|
|
Volumn 8, Issue 8, 2010, Pages 833-834
|
|
Avastin, ODAC, and the FDA: Are we drafting the right players?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
CAPECITABINE;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
PACLITAXEL;
PLACEBO;
RETINOIC ACID;
ADVANCED CANCER;
BREAST CANCER;
CANCER COMBINATION CHEMOTHERAPY;
CANCER RESISTANCE;
CANCER SURVIVAL;
CLINICAL TRIAL;
DRUG APPROVAL;
DRUG COST;
DRUG EFFICACY;
EDITORIAL;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LEUKEMIA;
OVERALL SURVIVAL;
PROGRESSION FREE SURVIVAL;
|
|
EID: 77957338088
PISSN: 15401405
EISSN: 15401413
Source Type: Journal
DOI: 10.6004/jnccn.2010.0061 Document Type: Editorial |
|
Times cited : (3)
|
|
References (0)
|
